Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | HPGD | P15428 | 4/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.77 |
| ▸ | PKM | P14618 | 2/20 | 0.77 |
| ▸ | NPC1 | O15118 | 2/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | HPGDS | O60760 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068020 | 0.90 | SMN1; SMN2 (0.71) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL13352016 | 0.90 | MEN1 (0.74) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL297188 | 0.90 | MEN1 (0.74) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| Tranilast SCHEMBL29876 | 0.87 | MEN1 (1.00) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| Tranilast SCHEMBL10978582 | 0.87 | MEN1 (1.00) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL9973827 | 0.87 | ALDH1A1 (0.82) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL13352244 | 0.87 | MEN1 (0.71) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| Tranilast SCHEMBL29875 | 0.87 | MEN1 (1.00) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL2845939 | 0.87 | MEN1 (0.82) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| Tranilast SCHEMBL8696829 | 0.87 | MEN1 (1.00) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185150-B1 | USE OF TRANILAST AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO KG (DE) | 2012-03-14 | — | — | EP | claimed |
| US-20110112187-A1 | Use Of Tranilast And Derivatives Thereof For The Therapy Of Neurological Conditions | SYGNIS BIOSCIENCE GMBH & CO. KG. (DE) | 2011-05-12 | — | — | US | claimed |
| EP-2185150-A1 | USE OF TRANILAST AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | Sygnis Bioscience GmbH & Co. KG (DE) | 2010-05-19 | — | — | EP | claimed |
| EP-2030617-A1 | Use of tranilast and derivatives thereof for the therapy of neurological conditions | Sygnis Bioscience GmbH & Co. KG (DE) | 2009-03-04 | — | — | EP | claimed |
| WO-2009024543-A1 | USE OF TRANILAST AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | claimed |
| EP-2185150-B1 | USE OF TRANILAST AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO KG (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20110112187-A1 | Use Of Tranilast And Derivatives Thereof For The Therapy Of Neurological Conditions | SYGNIS BIOSCIENCE GMBH & CO. KG. (DE) | 2011-05-12 | — | — | US | disclosed |
| EP-2185150-A1 | USE OF TRANILAST AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | Sygnis Bioscience GmbH & Co. KG (DE) | 2010-05-19 | — | — | EP | disclosed |
| EP-2030617-A1 | Use of tranilast and derivatives thereof for the therapy of neurological conditions | Sygnis Bioscience GmbH & Co. KG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2009024543-A1 | USE OF TRANILAST AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112187-A1 | Use Of Tranilast And Derivatives Thereof For The Therapy Of Neurological Conditions | BDNF, INA, SMN1; SMN2 | SMN1; SMN2 3/4885MEN1 2156/4885KMT2A 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.